Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

At the heart of innovation is T-win®, a groundbreaking vaccine platform that could change how we treat cancer.

Several oral abstracts presented at the American Society of Clinical Oncology’s annual meeting highlight ongoing research of Keytruda, Opdivo, Tecentriq and more in skin cancer.

Following a supervised exercise lowered people's risk of colon cancer recurrence by 28% in an extensive new clinical trial.

A panel of breast cancer thrivers touches on moving on after cancer, how to find joy during the dark hours of the journey, ...

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...

Leaders in oncology share why the American Society of Clinical Oncology (ASCO) meeting remains a top global gathering for breakthroughs, networking, and lifelong learning.

The Trump administration has proposed allocating $4.53 billion for the National Cancer Institute in fiscal year 2026, marking a 37.2% decrease from the $7.22 billion the NCI received in fiscal 2025.

Five early-career Fred Hutch/UW researchers received prestigious Young Investigator Awards from Conquer Cancer, the ASCO Foundation during this year's annual meeting of the American Society of ...

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

In the randomized dose-expansion phase of a Phase 1 study (NCT03460977), the combination of mevrometostat (1250 mg twice daily on an empty stomach) and enzalutamide (160 mg once daily) demonstrated ...